NAD+ Precursors: NMN vs. NR, Parsing the Evidence in 2025

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, central to energy metabolism, DNA repair, and sirtuin activity, proteins closely linked to longevity. NAD+ levels decline roughly 50% between age 40 and 60. The proposed solution: supplement with precursors. The two leading candidates are NMN and NR.

How They're Different

NR must first be converted to NMN before becoming NAD+. NMN skips that step. Early human trials (Washington University, Imai lab) showed oral NMN was absorbed, converted to NAD+ in blood, and improved insulin sensitivity in postmenopausal women with prediabetes. NR has more published human trials overall and shows consistent NAD+ elevation in blood, though the correlation to intracellular muscle NAD+ remains under investigation.

What the Evidence Actually Supports

As of 2025, neither compound has completed the large-scale, long-term trials needed to confirm longevity outcomes in humans. We have short-term trials (8-12 weeks) showing safe NAD+ elevation, some metabolic improvements, and preliminary data on muscle function. The dramatic animal study results have not replicated cleanly in humans, a recurring theme in longevity research.

Practical Guidance

• ✓NR: more human trial data, well-tolerated, typically 250-500 mg/day. Brands: Tru Niagen, Thorne.
• ✓NMN: promising early data, typically 250-500 mg/day. Sublingual forms may improve absorption.
• ✓Both show potential synergy with resveratrol or pterostilbene (sirtuin activators).
• ✓Cost: NR is generally 30-50% cheaper than NMN at equivalent doses.